TNFSF4 and cancer: Collectively,our findings suggest that the in situ gel vaccine, enriched with Dox,cGAMPnps, and either anti-PD-1 antibody or OX40L, can stimulate robustantitumor immunity, inhibit metastasis, and prevent cancer recurrencein the postsurgical 4T1 TNBC model.